Advanced

Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease

Cenci Nilsson, Angela LU ; Ohlin, Elisabet LU and Odin, Per LU (2011) In CNS and Neurological Disorders-Drug Targets 10(6). p.670-684
Abstract
Dyskinesia and motor fluctuations affect up to 90% of patients with Parkinson's disease (PD) within ten years of L-DOPA pharmacotherapy, and represent a major challenge to a successful clinical management of this disorder. There are currently two main treatment options for these complications, namely, deep brain electrical stimulation or continuous infusion of dopaminergic agents. The latter is achieved using either subcutaneous apomorphine infusion or enteric L-DOPA delivery. Some patients also benefit from the antidyskinetic effect of amantadine as an adjunct to L-DOPA treatment. Ongoing research in animal models of PD aims at discovering additional, novel treatment options that can either prevent or reverse dyskinesia and motor... (More)
Dyskinesia and motor fluctuations affect up to 90% of patients with Parkinson's disease (PD) within ten years of L-DOPA pharmacotherapy, and represent a major challenge to a successful clinical management of this disorder. There are currently two main treatment options for these complications, namely, deep brain electrical stimulation or continuous infusion of dopaminergic agents. The latter is achieved using either subcutaneous apomorphine infusion or enteric L-DOPA delivery. Some patients also benefit from the antidyskinetic effect of amantadine as an adjunct to L-DOPA treatment. Ongoing research in animal models of PD aims at discovering additional, novel treatment options that can either prevent or reverse dyskinesia and motor fluctuations. Alternative methods of continuous L-DOPA delivery (including gene therapy), and pharmacological agents that target nondopaminergic receptor systems are currently under intense experimental scrutiny. Because clinical response profiles show large individual variation in PD, an increased number of treatment options for dyskinesia and motor fluctuations will eventually allow for antiparkinsonian and antidyskinetic therapies to be tailor-made to the needs of different patients and/or PD subtypes. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Parkinson's disease, motor fluctuations, dyskinesia, motor, complications, basal ganglia, glutamate, serotonin, rodent, non-human, primate
in
CNS and Neurological Disorders-Drug Targets
volume
10
issue
6
pages
670 - 684
publisher
Bentham Science Publishers
external identifiers
  • wos:000295404000005
  • pmid:21838677
ISSN
1871-5273
DOI
10.2174/187152711797247885
language
English
LU publication?
yes
id
79524c14-24ea-4046-9c68-0e30a9a8cd4e (old id 2179523)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21838677?dopt=Abstract
date added to LUP
2011-11-01 07:47:07
date last changed
2016-04-15 16:05:31
@article{79524c14-24ea-4046-9c68-0e30a9a8cd4e,
  abstract     = {Dyskinesia and motor fluctuations affect up to 90% of patients with Parkinson's disease (PD) within ten years of L-DOPA pharmacotherapy, and represent a major challenge to a successful clinical management of this disorder. There are currently two main treatment options for these complications, namely, deep brain electrical stimulation or continuous infusion of dopaminergic agents. The latter is achieved using either subcutaneous apomorphine infusion or enteric L-DOPA delivery. Some patients also benefit from the antidyskinetic effect of amantadine as an adjunct to L-DOPA treatment. Ongoing research in animal models of PD aims at discovering additional, novel treatment options that can either prevent or reverse dyskinesia and motor fluctuations. Alternative methods of continuous L-DOPA delivery (including gene therapy), and pharmacological agents that target nondopaminergic receptor systems are currently under intense experimental scrutiny. Because clinical response profiles show large individual variation in PD, an increased number of treatment options for dyskinesia and motor fluctuations will eventually allow for antiparkinsonian and antidyskinetic therapies to be tailor-made to the needs of different patients and/or PD subtypes.},
  author       = {Cenci Nilsson, Angela and Ohlin, Elisabet and Odin, Per},
  issn         = {1871-5273},
  keyword      = {Parkinson's disease,motor fluctuations,dyskinesia,motor,complications,basal ganglia,glutamate,serotonin,rodent,non-human,primate},
  language     = {eng},
  number       = {6},
  pages        = {670--684},
  publisher    = {Bentham Science Publishers},
  series       = {CNS and Neurological Disorders-Drug Targets},
  title        = {Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease},
  url          = {http://dx.doi.org/10.2174/187152711797247885},
  volume       = {10},
  year         = {2011},
}